Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
November 07, 2023 08:00 ET
|
Clene Inc.
Reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8® in the RESCUE ALS open-label extension...
National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
October 05, 2023 10:00 ET
|
Clene Inc.
SALT LAKE CITY, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure,...
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action
September 28, 2023 08:00 ET
|
Clene Inc.
Novel catalytic mechanism of CNM-Au8 reveals its promise as a versatile new treatment to address multiple assaults on neuronal health in neurodegenerative diseases SALT LAKE CITY, Sept. 28, 2023 ...
Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
September 25, 2023 16:00 ET
|
Clene Inc.
SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...
Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
September 25, 2023 07:00 ET
|
Clene Inc.
Prolonged life with 49% decreased risk of death for participants in the HEALEY ALS Platform Trial treated with CNM-Au8® 30mg compared to PRO-ACT matched placebo over long-term follow-up,...
Clene to Present at Upcoming September Conferences
August 30, 2023 08:20 ET
|
Clene Inc.
SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...
Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up
August 29, 2023 07:00 ET
|
Clene Inc.
19.3 month significant survival difference for CNM-Au8® treated participants versus placebo52% significant decreased risk of ALS clinical worsening events Over 475 years of CNM-Au8 treatment exposure...
Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
August 14, 2023 08:00 ET
|
Clene Inc.
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) in patients treated with CNM-Au8® in the HEALEY ALS Platform...
Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023 07:00 ET
|
Clene Inc.
SALT LAKE CITY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
June 26, 2023 08:00 ET
|
Clene Inc.
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient follow-upSALT LAKE CITY, June 26, 2023 (GLOBE NEWSWIRE) --...